Vaccination, human mobility, and COVID-19 health outcomes: Empirical comparison before and during the outbreak of SARS-Cov-2 B.1.1.529 (Omicron) variant

被引:5
|
作者
Hu, Songhua [1 ]
Xiong, Chenfeng [2 ]
Zhao, Yingrui [3 ]
Yuan, Xin [2 ]
Wang, Xuqiu [2 ]
机构
[1] Univ Maryland, Dept Civil & Environm Engn, College Pk, MD 20742 USA
[2] Villanova Univ, Dept Civil & Environm Engn, Villanova, PA 19085 USA
[3] Univ Maryland, Dept Geog Sci, College Pk, MD 20742 USA
基金
美国国家卫生研究院;
关键词
COVID-19; Vaccination; Human mobility; Omicron; Disparity; Mediation analysis; DATA REVEAL;
D O I
10.1016/j.vaccine.2023.05.056
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The B.1.1.529 (Omicron) variant surge has raised concerns about the effectiveness of vaccines and the impact of imprudent reopening. Leveraging over two years of county-level COVID-19 data in the US, this study aims to investigate relationships among vaccination, human mobility, and COVID-19 health out-comes (assessed via case rate and case-fatality rate), controlling for socioeconomic, demographic, racial/ethnic, and partisan factors. A set of cross-sectional models was first fitted to empirically compare disparities in COVID-19 health outcomes before and during the Omicron surge. Then, time-varying medi-ation analyses were employed to delineate how the effects of vaccine and mobility on COVID-19 health outcomes vary over time. Results showed that vaccine effectiveness against case rate lost significance during the Omicron surge, while its effectiveness against case-fatality rate remained significant through-out the pandemic. We also documented salient structural inequalities in COVID-19-related outcomes, with disadvantaged populations consistently bearing a larger brunt of case and death tolls, regardless of high vaccination rates. Last, findings revealed that mobility presented a significantly positive relation-ship with case rates during each wave of variant outbreak. Mobility substantially mediated the direct effect from vaccination to case rate, leading to a 10.276 % (95 % CI: 6.257, 14.294) decrease in vaccine effectiveness on average. Altogether, our study implies that sole reliance on vaccination to halt COVID-19 needs to be re-examined. Well-resourced and coordinated efforts to enhance vaccine effectiveness, mitigate health disparity and selectively loosen non-pharmaceutical interventions are essential to bring-ing the pandemic to an end.& COPY; 2023 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5097 / 5112
页数:16
相关论文
共 50 条
  • [1] COVID-19 vaccination and SARS-CoV-2 Omicron (B.1.1.529) variant: a at the end of the tunnel?
    Mattiuzzi, Camilla
    Henry, Brandon M.
    Lippi, Giuseppe
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 118 : 167 - 168
  • [2] SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19
    Afshar, Zeinab Mohseni
    Pirzaman, Ali Tavakoli
    Karim, Bardia
    Anaraki, Shiva Rahimipour
    Hosseinzadeh, Rezvan
    Pireivatlou, Elaheh Sanjari
    Babazadeh, Arefeh
    Hosseinzadeh, Dariush
    Miri, Seyed Rouhollah
    Sio, Terence T.
    Sullman, Mark J. M.
    Barary, Mohammad
    Ebrahimpour, Soheil
    DIAGNOSTICS, 2023, 13 (03)
  • [3] Pregnancy Outcomes Before and After the Emergence of the SARS-CoV-2 B.1.1.529 (Omicron) Variant
    Seif, Karl
    Desai, Andrea
    Mangione, Mary
    Tadbiri, Hooman
    Turan, Shifa
    Wolfe, Alexa
    OBSTETRICS AND GYNECOLOGY, 2023, 141 : 29S - 29S
  • [4] Neutralizing potency of COVID-19 vaccines against the SARS-CoV-2 Omicron (B.1.1.529) variant
    Lippi, Giuseppe
    Mattiuzzi, Camilla
    Henry, Brandon M.
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (05) : 1799 - 1802
  • [5] Emerging evidence on Omicron (B.1.1.529) SARS-CoV-2 variant
    Sharma, Vineet
    Rai, Himanshu
    Gautam, Dev N. S.
    Prajapati, Pradeep K.
    Sharma, Rohit
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (05) : 1876 - 1885
  • [6] Omicron variant (B.1.1.529) of SARS-CoV-2: Threat for the elderly?
    Chavda, Vivek P.
    Apostolopoulos, Vasso
    MATURITAS, 2022, 158 : 78 - 81
  • [7] A SARS-CoV-2 omicron (B.1.1.529) variant outbreak in a primary school in Geneva, Switzerland
    Lorthe, Elsa
    Bellon, Mathilde
    Berthelot, Julie
    Michielin, Gregoire
    L'Huillier, Arnaud G.
    Posfay-Barbe, Klara M.
    Azman, Andrew S.
    Guessous, Idris
    Maerkl, Sebastian J.
    Eckerle, Isabella
    Stringhini, Silvia
    LANCET INFECTIOUS DISEASES, 2022, 22 (06): : 767 - 768
  • [8] COVID-19-Related Symptoms during the SARS-CoV-2 Omicron (B.1.1.529) Variant Surge in Japan
    Akaishi, Tetsuya
    Kushimoto, Shigeki
    Katori, Yukio
    Sugawara, Noriko
    Egusa, Hiroshi
    Igarashi, Kaoru
    Fujita, Motoo
    Kure, Shigeo
    Takayama, Shin
    Abe, Michiaki
    Kikuchi, Akiko
    Ohsawa, Minoru
    Ishizawa, Kota
    Abe, Yoshiko
    Imai, Hiroyuki
    Inaba, Yohei
    Iwamatsu-Kobayashi, Yoko
    Nishioka, Takashi
    Onodera, Ko
    Ishii, Tadashi
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2022, 258 (02): : 103 - 110
  • [9] The SARS-CoV-2 Omicron (B.1.1.529) variant and the re-emergence of COVID-19 in Europe: An alarm for Bangladesh
    Islam, Md. Rabiul
    HEALTH SCIENCE REPORTS, 2022, 5 (02)
  • [10] Rapid Detection of the Omicron (B.1.1.529) SARS-CoV-2 Variant Using a COVID-19 Diagnostic PCR Assay
    Ippoliti, Chiara
    De Maio, Flavio
    Santarelli, Giulia
    Marchetti, Simona
    Vella, Antonietta
    Santangelo, Rosaria
    Sanguinetti, Maurizio
    Posteraro, Brunella
    MICROBIOLOGY SPECTRUM, 2022, 10 (04):